Avacta has announced positive early efficacy data for its peptide drug conjugate, AVA6000, demonstrating clinically meaningful tumour shrinkage in patients with salivary gland cancer (SGC). 

AVA6000 consists of doxorubicin chemotherapy conjugated with Avacta’s pre|CISION peptide, specifically cleaved by fibroblast activation protein-alpha (FAP) in the tumour microenvironment.

It is currently in a Phase I trial in patients with FAP-positive solid tumours. 

The key findings: 

  • Among 10 patients treated at the dose of 250mg/m2 and above, five patients demonstrate tumour shrinkage (one partial and four minor responses) 
  • Six of these 10 patients are continuing treatment and an additional two patients, who have reached maximum cycles, are still in follow up for progression free survival 
  • The safety profile of AVA6000 continues to demonstrate a robust reduction in severe haematologic and cardiac toxicities that are associated with conventional dose doxorubicin 

Based on these data, Avacta has initiated three Phase Ib expansion cohorts in triple negative breast cancer, soft tissue sarcoma and salivary gland cancer in the first and second line setting. 

Christina Coughlin, CEO of Avacta, commented: “These data highlight the transformative potential of our pre|CISION peptide drug conjugates in expanding the efficacy of highly potent therapeutics and support our growing optimism in this programme. Salivary gland cancer is a devastating disease with no established standard of care treatment options. AVA6000 demonstrated a clinically meaningful tumour shrinkage in SGC patients, highlighting its potential as an important new treatment option for patients with SGC and other solid tumours.” 

SGC accounts for 6-8% of head and neck cancers in the US, with approximately 2,500 cases diagnosed in the US each year. There is no standard of care for SGC once patients have developed distant metastasis, with a five year survival rate of approximately 43%.

Diana Spencer, Senior Digital Content Editor, DDW